Who is sponsoring NCT05975593?

NCT05975593 is sponsored by Washington University School of Medicine.

What drugs are being tested in NCT05975593?

Interventions in NCT05975593: Tumor collection via biopsy, Blood collection, Diffusion basis spectrum imaging (DBSI) magnetic resonance imaging (MRI).

What condition does NCT05975593 study?

NCT05975593 studies Locally Advanced Cervical Carcinoma, Locally Advanced Cervical Cancer, Locally Advanced Pancreas Cancer, Locally Advanced Pancreatic Carcinoma, Locally Advanced Pancreatic Cancer, Cervical Cancer, Pancreas Cancer, Pancreatic Cancer, Cancer of the Cervix, Cancer of the Pancreas.

Is NCT05975593 still recruiting?

NCT05975593 is currently recruiting now. Last updated 12 November 2025.

Last reviewed 2025-11-12 · How we verify

NCT05975593: METEOR-CRATR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial

Recruiting now NA Last updated 12 November 2025

What this trial tests

NA trial testing Tumor collection via biopsy in Locally Advanced Cervical Carcinoma in 60 participants. Currently enrolling.

Timeline

11 January 2024

Primary endpoint
31 December 2032

31 December 2032

Quick facts

Lead sponsor	Washington University School of Medicine
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	60
Start date	11 January 2024
Primary completion	31 December 2032
Estimated completion	31 December 2032
Sites	1 location across United States

Drugs / interventions tested

Tumor collection via biopsy
Blood collection — full drug profile →
Diffusion basis spectrum imaging (DBSI) magnetic resonance imaging (MRI)

Conditions studied

Locally Advanced Cervical Carcinoma — all drugs for Locally Advanced Cervical Carcinoma →
Locally Advanced Cervical Cancer — all drugs for Locally Advanced Cervical Cancer →
Locally Advanced Pancreas Cancer — all drugs for Locally Advanced Pancreas Cancer →
Locally Advanced Pancreatic Carcinoma — all drugs for Locally Advanced Pancreatic Carcinoma →

Sponsor

Washington University School of Medicine

Who can join

18 and older, any sex, with Locally Advanced Cervical Carcinoma or Locally Advanced Cervical Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a dynamically adjustable prospective longitudinal study designed to capture biospecimen (biopsy, blood, surgical) and multimodal treatment-related data (imaging, dosimetry, clinical) before, during, and after treatment with definitive-intent chemoradiotherapy for patients with locally advanced cervical and pancreatic cancer.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Radiation Oncology-Biology Integration Network (ROBIN): Bridging the gap between biological research and clinical practice.
Gregucci F, Lee-Poturalski C, Dirrim M, Stewart J, et al · · 2026 · PMID 41941260 · DOI 10.1158/1078-0432.ccr-25-1216

Verify or expand the search:

Other recruiting trials for Locally Advanced Cervical Carcinoma

Currently open trials in the same condition.

NCT06529809 — Accelerated Brachytherapy Forward Chemo Radiation Therapy (ABC-RT) for Locally-advanced Cervical Cancer · Phase 1, PHASE2 · recruiting
NCT06398938 — Evaluation of Ultraaccelerated High Dose Rate Intrauterine Interventional Radiotherapy · recruiting
NCT05722288 — Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in · Phase 2 · recruiting
NCT05462379 — Autologous Heterotopic Fresh Ovarian Graft in Woman With LACC Eligible for Pelvic Radiotherapy Treatment. · Phase 1, PHASE2 · active not recruiting
NCT05406856 — PROTECT: On-line Adaptive Proton Therapy for Cervical Cancer · NA · recruiting

Other Washington University School of Medicine trials

Trials by the same sponsor.

NCT05521997 — Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer · Phase 2 · not yet recruiting
NCT07101666 — Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer · Phase 2 · not yet recruiting
NCT07200089 — Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) · Phase 1 · not yet recruiting
NCT07313592 — Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients · not yet recruiting
NCT07419464 — 5-Fluorouracil Response and Optimization STudy (The FROST Trial) · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05975593 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Washington University School of Medicine
Last refreshed: 12 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05975593.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing